Christina Bookwalter, PharmD, MS MEd, BCPS, BCACP

home / authors / christina-bookwalter-pharmd-ms-med-bcps-bcacp

Articles

biosimilar cost savings

The Evolution of Biologics and Biosimilars: Reducing Costs and Improving Accessibility Through Pharmacist Engagement

Christina Bookwalter, PharmD, MS MEd, BCPS, BCACP
May 20th 2024

Original biologic products, and more recently biosimilar products, are a groundbreaking advancement in modern medical treatments. Pharmacists should understand biologic products and concerns with biosimilars.

Read More

Urinary tract infection vaccination and treatment -- Image credit: Vitalii Vodolazskyi | stock.adobe.com

Unlocking Hope: The MV140 Vaccine for Recurrent Urinary Tract Infections

Christina Bookwalter, PharmD, MS MEd, BCPS, BCACP
May 20th 2024

A review of the literature shows the sublingual vaccine holds promise for the treatment of this condition.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD